Singapore, Feb. 16 -- PharmaEssentia Corporation, a global biopharmaceutical company headquartered in Taiwan with deep expertise in the development of novel biologics for hematology and oncology, and its US subsidiary PharmaEssentia USA Corporation have announced that the global corporate Board of Directors has approved an investment of approximately $46 million to establish a new, wholly owned manufacturing subsidiary in Puerto Rico.

The planned investment supports the company's global manufacturing expansion strategy and is intended to serve as a future manufacturing centre for the US market and long-term global demand for BESREMi(R) (ropeginterferon alfa-2b).

The investment reflects sustained global demand growth for BESREMi(R), part...